Published in Epilepsy Res on October 01, 2010
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Antiepileptic drugs prescription utilization behavior and direct costs of treatment in a national hospital of India. Ann Indian Acad Neurol (2012) 0.93
Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients. Drugs Real World Outcomes (2016) 0.75
Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan. Neurosciences (Riyadh) (2016) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol (2014) 1.62
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Familial mesial temporal lobe epilepsy (FMTLE) : a clinical and genetic study of 15 Italian families. J Neurol (2007) 1.54
Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology (2014) 1.52
Physiologic autonomic arousal heralds motor manifestations of seizures in nocturnal frontal lobe epilepsy: implications for pathophysiology. Sleep Med (2012) 1.51
Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet (2012) 1.48
Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis. J Res Med Sci (2012) 1.47
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
A 7 Mb duplication at 22q13 in a girl with bipolar disorder and hippocampal malformation. Am J Med Genet A (2008) 1.41
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
Autosomal dominant lateral temporal epilepsy: clinical spectrum, new epitempin mutations, and genetic heterogeneity in seven European families. Epilepsia (2003) 1.27
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain (2006) 1.18
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging (2006) 1.15
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia (2009) 1.11
Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol (2008) 1.10
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
Increased frequency of arousal parasomnias in families with nocturnal frontal lobe epilepsy: a common mechanism? Epilepsia (2010) 1.08
EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05
Improving upper limb motor functions through action observation treatment: a pilot study in children with cerebral palsy. Dev Med Child Neurol (2012) 1.05
Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins. Epilepsy Res (2008) 1.04
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res (2003) 1.01
Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia (2013) 1.01
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia (2010) 0.99
Excessive daytime sleepiness and subjective sleep quality in patients with nocturnal frontal lobe epilepsy: a case-control study. Epilepsia (2006) 0.98
Unexpected gamma glutamyltransferase rise increase during levetiracetam monotherapy. Epileptic Disord (2010) 0.97
New and forthcoming anti-epileptic drugs. Curr Opin Neurol (2011) 0.97
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia (2002) 0.95
Treatment of epilepsy in developing countries. BMJ (2007) 0.94
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs. Epilepsia (2009) 0.94
Lateralizing value of the auditory aura in partial seizures. Epilepsia (2006) 0.93
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia (2014) 0.93
Benign childhood focal epilepsies. Epilepsia (2012) 0.93
Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia (2011) 0.91
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia (2014) 0.91
Knowledge and attitudes toward epilepsy among primary and secondary schoolteachers in Italy. Epilepsy Behav (2011) 0.90
Seizure outcome of epilepsy surgery in focal epilepsies associated with temporomesial glioneuronal tumors: lesionectomy compared with tailored resection. J Neurosurg (2009) 0.90
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol (2005) 0.90
Abnormal brain processing of cutaneous pain in patients with chronic migraine. Pain (2003) 0.90
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res (2006) 0.88
Sudden unexpected death in epilepsy (SUDEP): a pilot study on truth telling among Italian epileptologists. Neurol Sci (2010) 0.88
Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol (2004) 0.88
A de novo LGI1 mutation in sporadic partial epilepsy with auditory features. Ann Neurol (2004) 0.88
Severe pulmonary congestion in a near miss at the first seizure: further evidence for respiratory dysfunction in sudden unexpected death in epilepsy. Epilepsy Behav (2009) 0.88
Prevalence of primary focal or segmental dystonia in adults in the district of foggia, southern Italy: a service-based study. Neuroepidemiology (2009) 0.87
Nocturnal frontal lobe epilepsy. Curr Neurol Neurosci Rep (2014) 0.87
Does the prion protein gene 129 codon polymorphism influence sleep? Evidence from a fatal familial insomnia kindred. Clin Neurophysiol (2002) 0.87
Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res (2004) 0.87
Prognostic factors in patients with mesial temporal lobe epilepsy. Epilepsia (2009) 0.87
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia (2006) 0.87
Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother (2008) 0.87
Novel medications for epilepsy. Drugs (2011) 0.86
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol (2009) 0.86
Praxis-induced seizures misdiagnosed as cataplexy: a case report. Mov Disord (2008) 0.86
Epileptic myoclonus as ciprofloxacin-associated adverse effect. Mov Disord (2007) 0.86
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.86
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs (2009) 0.86
Glossopharyngeal neuralgia responding to pregabalin. Headache (2006) 0.86
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol (2002) 0.86
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia (2014) 0.86
Complex segmental duplications mediate a recurrent dup(X)(p11.22-p11.23) associated with mental retardation, speech delay, and EEG anomalies in males and females. Am J Hum Genet (2009) 0.85